Micafungin Sodium Solvate Crystallization Stability

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Micafungin sodium, an anti-fungal drug, has poor stability and is difficult to crystallize, leading to quality issues during transportation and storage, and existing methods for obtaining stable forms are limited, hindering its pharmaceutical development.

Innovation Solution

A solvate of micafungin sodium is developed, comprising 2 molecules of crystalline water and 0.5 molecule of methanol, which forms column-like crystals with improved stability and ease of filtration, using a three-phase solvent system and specific crystallization conditions.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Stability of the object's composition

If the compound of formula I is precipitated by adding acetone and ethyl acetate to give amorphous form, then the compound can be obtained, but the stability is poor and quality is affected by degraded products during transportation or long-term preservation

Engineering Contradiction:
ImprovestabilityVSAvoidquality
Core Design Contradiction:
Stability of the object's compositionVSReliability

Solution Approach 1:

The patent changes the physical state parameter of the compound from amorphous to crystalline form by controlling crystallization conditions (solvent system, temperature, pH), thereby improving stability while maintaining quality

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent creates a composite crystalline structure incorporating the compound of formula I with specific solvents (acetone, ethyl acetate, isopropanol, water) in defined ratios to form a stable solvate with improved reliability

Inventive Principle:
Principle #40Composite materials

2Stability of the object's composition

If the compound of formula I is crystallized, then stability is improved, but it is difficult to crystallize and generally remains amorphous

Engineering Contradiction:
ImprovestabilityVSAvoidease of crystallization
Core Design Contradiction:
Stability of the object's compositionVSEase of manufacture

Solution Approach 1:

The patent uses specific solvents (acetone, ethyl acetate, isopropanol, water) as intermediaries to facilitate crystallization of the compound of formula I, transforming it from difficult-to-crystallize amorphous form to stable crystalline form through controlled solvation and crystallization processes

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes manufacturing parameters including solvent composition ratios, temperature ranges (0-25°C), and pH conditions to enable crystallization while maintaining ease of manufacture

Inventive Principle:
Principle #35Parameter changes

3Quantity of substance

If the content of solvent in the precipitate is reduced below standard by extending drying time, then solvent content is reduced, but the degraded products increase and quality is reduced

Engineering Contradiction:
Improvesolvent contentVSAvoidquality
Core Design Contradiction:
Quantity of substanceVSReliability

Solution Approach 1:

The patent optimizes drying parameters (temperature, time, pressure) to achieve the desired solvent content reduction while minimizing degradation, balancing quantity and quality requirements

Inventive Principle:
Principle #35Parameter changes

4Shape

If needle-like crystals of B82 type are obtained, then crystal form is achieved, but filtration is difficult and operation time is long

Engineering Contradiction:
Improvecrystal formVSAvoidease of filtration
Core Design Contradiction:
ShapeVSEase of operation

Solution Approach 1:

The patent changes crystallization parameters (solvent system, temperature, pH) to produce crystals with improved morphology that are easier to filter while maintaining the desired crystal form characteristics

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The solvate provides a stable form of micafungin sodium, facilitating easier production and storage, and can be converted to solvent-free crystals, enhancing its stability and usability in various pharmaceutical formulations.

Implementation Method 1

a solvate of micafungin sodium is developed, comprising 2 molecules of crystalline water and 0.5 molecule of methanol, which forms column-like crystals with improved stability and ease of filtration, using a three-phase solvent system and specific crystallization conditions

Methodology Applied
Scientific EffectCrystallization: Crystallisation

Data Source

PatentEP3150623B1Solvate of cyclic peptide compound, preparation method for same, and uses thereof
Publication Date: 2019.04.03 SHANGHAI TECHWELL BIOPHARMACEUTICALS CO LTD
  • EP3150623B1 patent drawingFigure 1~2
  • EP3150623B1 patent drawingFigure 3
  • EP3150623B1 patent drawingFigure 4~5

AI summary

Provided in the invention is a solvate of a cyclic peptide compound, represented byformula I is the structural formula of the cyclic peptide compound, and, also disclosed are a preparation method for same and uses thereof.